Deal-Making Trends in Pharma – Thematic Research

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

To gain a better understanding of the pharmaceutical deal landscape, this report will dive into three separate deal categories: strategic partnerships, licensing activity, and M&A activity. Furthermore, the categories will be further broken down by four dominating therapeutic themes. These include gene therapy, immuno-oncology, microbiome, and orphan drugs. These themes are among those expected to have the greatest presence in deals made within the pharmaceutical industry, which is indicative of the optimism surrounding their future potential. Please also note that this report only covers select geographies, North America, Europe, and Asia-Pacific, the three regions with the highest deal volume and value. These regions were also chosen to be covered in this report based on the fact that they are hotspots for the development of innovative drugs.
This report also identifies target drug companies that would be strong acquisition target candidates. The companies identified include those that have drugs that fall into one of the four major themes discussed in this report: gene therapy, immuno-oncology, microbiome, and/or orphan drugs. Chosen targets were also selected on the basis of having drugs in both the preclinical stage and clinical stage settings. Identified targets are also all privately owned, and have seen little to no recent merger and acquisition (M&A) activity in the past five years. Lastly, the list of targets also includes those have had recent positive clinical trial data.

Scope

GlobalData’s Deal-Making Trends in Pharma report provides with in-house expertise to provide an assessment of the deal landscape within the pharmaceutical industry.

Components of the report include:

Data analysis, trends, and insights for strategic partnerships, licensing activity, and M&A activity within the pharmaceutical industry

Data analysis, trends, and insights for deals that encompass specific therapeutic themes (gene therapy, immuno-oncology, microbiome, and orphan drugs)

Data analysis, trends, and insights for deals that have occurred in select geographies (North America, Europe, and Asia-Pacific)

Identification of drug companies that would be strong acquisition target candidates

Reasons to Buy

Gain a better understating of the volume and value dynamics within the pharmaceutical deal space.

Develop and design your corporate strategies through an in-house expert analysis of deals impacting the healthcare industry.

Stay up to date on the industry’s most impactful deals that have been completed within the past 5 years, along with a glimpse of deals completed or to be completed in 2019.

Identify emerging deal trends, as they relate to deal type, therapeutic theme, geography, to gain a competitive advantage.

Identify drug companies that would be strong acquisition target candidates.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Deal-Making and the Importance of Themes

3.1 Huge Deals in 2019

3.1.1 Takeda Acquires Shire

3.1.2 Bristol-Myers Squibb Acquiring Celgene

3.2 Strategic Partnerships

3.3 Licensing Agreements

3.4 Mergers and Acquisitions

3.5 Gene Therapy

3.6 Immuno-Oncology

3.7 Microbiome

3.8 Orphan Drugs

3.9 Geographical Breakdown and Comparison

4 Strategic Partnership Activity over the Last Five Years

4.1 A Closer Look at Partnership Activity (key themes and factors driving deals)

4.1.1 Gene Therapy

4.1.2 Immuno-Oncology

4.1.3 Microbiome

4.1.4 Orphan Drugs

4.2 Valuations

4.3 Case Studies

4.3.1 Gene Therapy

4.3.2 Immuno-Oncology

4.3.3 Microbiome

4.3.4 Orphan Drugs

5 Licensing Activity over the Last Five Years

5.1 A Closer Look at Licensing Activity (key themes and factors driving deals)

5.1.1 Gene Therapy

5.1.2 Immuno-Oncology

5.1.3 Microbiome

5.1.4 Orphan Drugs

5.2 Valuations

5.3 Case Studies

5.3.1 Gene Therapy

5.3.2 Immuno-Oncology

5.3.3 Microbiome

5.3.4 Orphan Drugs

6 Merger and Acquisition Activity over the Last Five Years

6.1 A Closer Look at Merger and Acquisition Activity (key themes and factors driving deals)

6.1.1 Gene Therapy

6.1.2 Immuno-Oncology

6.1.3 Microbiome

6.1.4 Orphan Drugs

6.2 Valuations

6.3 Case Studies

6.3.1 Gene Therapy

6.3.2 Immuno-Oncology

6.3.3 Microbiome

6.3.4 Orphan Drugs

7 What Does It Mean?

7.1 Strategic Partnerships

7.2 Licensing Agreements

7.3 Mergers and Acquisitions

8 Outlook for Deal-Making in Pharma

9 Appendix: Our “Thematic” Research Methodology

9.1 Deals and Thematics Analysis Methodology

9.2 Viewing the world’s data by themes makes it easier to make important decisions

9.3 Traditional Thematic Research Does a Poor Job of Picking Winners and Losers

9.4 Introducing GlobalData’s Thematic Engine

9.5 This is how it works

9.6 How Our Research Reports Fit Into Our Overall Research Methodology

9.7 About GlobalData

9.8 Contact us

9.9 Disclaimer

Frequently asked questions

Deal-Making Trends in Pharma – Thematic Research thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Deal-Making Trends in Pharma – Thematic Research was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Deal-Making Trends in Pharma – Thematic Research in real time.

  • Access a live Deal-Making Trends in Pharma – Thematic Research dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.